LEKSUM Signs Agreement with Medical University of Vienna for Preparatory Work Leading to Phase I/II Clinical Trials

BOSTON, MA - OCTOBER 13, 2026

Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, is proud to announce that it recently signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at Medical University of Vienna covering the preparatory work leading up to the Phase I/II first-in-human clinical trials for LK-ICU. Preclinical studies of LK-ICU, which consists of extracellular vesicles derived from bone marrow mesenchymal stromal cells, indicate an almost complete preservation of both diaphragm muscle fiber size and function normally associated with the use of mechanical ventilation. Extended weaning from mechanical ventilation, often resulting from ICU-acquired weakness, is estimated to impact the quality-of-life of hundreds of thousands of patients a year in the U.S. and Europe.

To view the full announcement, including downloadable images, bios, and more, click here.

• Leksum signs an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna, with Phoenestra GmbH as a co-signatory, to conduct preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU.
• Preclinical studies show LK-ICU, consisting of extracellular vesicles derived from bone marrow mesenchymal stromal cells, nearly completely preserves diaphragm muscle fiber size and function during mechanical ventilation.
• Leksum plans to start efforts under the agreement upon closing its Series A, expects the planning phase to last several months, and intends to use European clinical data to support its U.S. regulatory path.

Click image above to view full announcement.

Leksum LLC, based in Boston, Massachusetts, is an early-stage life sciences company developing advanced biologic therapies to address acquired muscle myopathies. In addition to LK-ICU, Leksum's pipeline includes skeletal muscle conditions including sarcopenia, cancer cachexia, and muscle-loss due to the use of weight-loss drugs (i.e., GLP-1s).

Niles Chura
[email protected]

Source: Leksum

Distributed by: Reportable, Inc.

This contant was orignally distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is LEKSUM Signs Agreement with Medical University of Vienna for Preparatory Work Leading to Phase I/II Clinical Trials.